Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.
Risk of vascular disease in patients with multiple sclerosis: a review.
Contribution of imaging to the diagnosis of optic neuropathies.
Oral Agent Outcomes
The use of aminopyridines in neurological disorders.
160 Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis.
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.
Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders.
Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.
Epitope spreading in immune-mediated diseases: implications for immunotherapy.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice.
Self-reported incidence and age of onset of chronic comorbid medical conditions in adults aging with long-term physical disability.
A new cognitive rehabilitation programme for patients with multiple sclerosis: the 'MS-line! Project'
The potential for new therapeutic approaches: Global research collaboration examines multiple pathways of neuroprotection in Huntington disease
Resolution of autoimmune thrombocytopenia associated with raltegravir use in an HIV-positive patient.
Clonally expanded mitochondrial DNA deletions within the choroid plexus in multiple sclerosis.
Multiple sclerosis and sexual dysfunction.
Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients.
Neuropsychological Aspects of Childhood Multiple Sclerosis: An Overview.
Non-lesional white matter changes in pediatric multiple sclerosis and monophasic demyelinating disorders.
Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
A signal-to-noise-ratio-based analysis of multifocal visual-evoked potentials in multiple sclerosis risk assessment.

Pages